In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of treatment Tirzepatide users experienced greater waistline reduction (7. ...

A five-year trial of the weight loss drug tirzepatide in Greater Manchester was announced last October ...

Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight and keep it off. First head-to-head trial compares tirzepatide and semaglutide - Results are in ...

The tirzepatide group had more injection-site reactions than the semaglutide group, which is consistent with other SURMOUNT trials. 14,20 In the current trial, no participants were reported to ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with menopause hormone therapy. A Mayo Clinic study revealed that this dual ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference. Fox News Media Fox Business ...

In real-world cohort, percentage weight reduction at 1 year was 3.6%, 6.8%, and 11.9% with early and late discontinuation and nondiscontinuation, respectively.

Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use as a treatment for obstructive sleep apnoea (OSA) after hitting the mark in a pair of phase 3 trials.

Tirzepatide dose escalation is slower in real-world settings than clinical trials among individuals without type 2 diabetes (T2D) but with multiple comorbidities, according to study results ...

HealthDay News — For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7% on average, which is lower than the percentages reported ...